33 Recruiting Studies Using Pirtobrutinib
Active clinical trials that use this intervention, sourced directly from the NIH registry.
Browse by conditionTrials Using Pirtobrutinib
Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)
📍 Alaska Oncology and Hematology, LLC — Anchorage, Alaska
Lymphoma, Mantle-Cell
View Study & Checklist ➔Pirtobrutinib and Venetoclax With MRD Detection for Previously Untreated Chronic Lymphocytic Leukemia
📍 Mayo Clinic in Rochester — Rochester, Minnesota
Chronic Lymphocytic Leukemia
View Study & Checklist ➔Pirtobrutinib and Venetoclax in Waldenström Macroglobulinemia
📍 Beth Israel Deaconness Medical — Boston, Massachusetts
Waldenstrom Macroglobulinemia
View Study & Checklist ➔GATE1: A Multicenter Phase II Study of Pirtobrutinib, Rituximab and Venetoclax Combination Therapy for Patients With Previously Untreated Mantle Cell Lymphoma
📍 Mayo Clinic in Rochester — Rochester, Minnesota
Mantle Cell Lymphoma
View Study & Checklist ➔Study of LOXO-305 (Pirtobrutinib) Versus Investigator's Choice (Idelalisib Plus Rituximab or Bendamustine Plus Rituximab) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
📍 Southern Cancer Center, P.C. — Daphne, Alabama
Chronic Lymphocytic Leukemia
View Study & Checklist ➔A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
📍 Ironwood Physicians, Ironwood Cancer and Research Centers — Chandler, Arizona
Chronic Lymphocytic Leukemia
View Study & Checklist ➔A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
📍 California Research Institute — Los Angeles, California
Chronic Lymphocytic Leukemia
View Study & Checklist ➔Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome
📍 O'Neal Comprehensive Cancer Center at University of Alabama at Birmingham — Birmingham, Alabama
Relapsed/Refractory Chronic Lymphocytic Leukemia
View Study & Checklist ➔Mosunetuzumab in Combination With Pirtobrutinib in Patients With Relapsed or Refractory Waldenstrom Macroglobulinemia (MPOWER)
📍 Huntsman Cancer Institute at University of Utah — Salt Lake City, Utah
Waldenstrom Macroglobulinemia
View Study & Checklist ➔Immune Profiling of CLL/SLL Treated With First-Line Pirtobrutinib
📍 National Institutes of Health Clinical Center — Bethesda, Maryland
Chronic Lymphocytic Leukemia (CLL)
View Study & Checklist ➔A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
📍 Mitchell Cancer Institute — Mobile, Alabama
Chronic Lymphocytic Leukemia
View Study & Checklist ➔Mosunetuzumab for CLL MRD Clearance
📍 Brigham & Women's Hospital — Boston, Massachusetts
Leukemia
View Study & Checklist ➔ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL
📍 Orchard Healthcare Research — Skokie, Illinois
CLL / SLL
View Study & Checklist ➔A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
📍 Cancer Specialists, LLC — Jacksonville, Florida
Chronic Lymphocytic Leukemia
View Study & Checklist ➔Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma
📍 University of California, Davis — Davis, California
Mantle Cell Lymphoma
View Study & Checklist ➔Pirtobrutinib and Mosunetuzumab for the Treatment of Relapsed/Refractory Grades 1-3A Follicular Lymphoma, PROMOTE-FL Trial
📍 Fred Hutch/University of Washington Cancer Consortium — Seattle, Washington
Grade 1 Follicular Lymphoma
View Study & Checklist ➔Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)
📍 M D Anderson Cancer Center — Houston, Texas
Leukemia
View Study & Checklist ➔Phase II Study of Combined Pirtobrutinib, Venetoclax and Obinutuzumab (PVO) Time-limited Treatment for Patients With Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL).
📍 MD Anderson Cancer Center — Houston, Texas
Chronic Lymphocytic Leukemia
View Study & Checklist ➔A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
📍 Sylvester Comprehensive Cancer Center — Miami, Florida
Chronic Lymphocytic Leukemia
View Study & Checklist ➔Fixed Duration Pirtobrutinib and Obinutuzumab in Chronic Lymphocytic Leukemia
📍 New England Cancer Specialists — Scarborough, Maine
Chronic Lymphocytic Leukemia
View Study & Checklist ➔Phase II Study of Pirtobrutinib, Rituximab (PR) in Previously Untreated Low and Intermediate Risk MCL (Mantle Cell Lymphoma) Patients
📍 MD Anderson Cancer Center — Houston, Texas
Mantle Cell Lymphoma
View Study & Checklist ➔Phase II Study of Pirtobrutinib With Venetoclax In Relapsed-Refractory MCL (Mantle Cell Lymphoma) Patients
📍 M D Anderson Cancer Center — Houston, Texas
Mantle Cell Lymphoma
View Study & Checklist ➔Pirtobrutinib (LOXO-305) and Venetoclax for the Treatment of Patients With CLL or SLL Resistant to Covalent BTKi
📍 Ohio State University Comprehensive Cancer Center — Columbus, Ohio
Chronic Lymphocytic Leukemia
View Study & Checklist ➔A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)
📍 Dana Farber Cancer Institute (Data Collection and Specimen Analysis) — Boston, Massachusetts
Waldenstrom Macroglobulinemia
View Study & Checklist ➔Pirtobrutinib in Combination With Rituximab in Adults With Untreated Marginal Zone Lymphoma (PIONEER-MZL)
📍 Washington University — St Louis, Missouri
Marginal Zone Lymphoma
View Study & Checklist ➔Phase 2 Open Label Randomized Study of Pirtobrutinib and Brexucabtagene Autoleucel in R/R MCL
📍 Stanford Cancer Center — Stanford, California
Mantle Cell Lymphoma
View Study & Checklist ➔Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation
📍 Winship Cancer Institute at Emory University — Atlanta, Georgia
Chronic Lymphocytic Leukemia
View Study & Checklist ➔A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
📍 Pacific Cancer Medical Center, Inc — Anaheim, California
Chronic Lymphocytic Leukemia
View Study & Checklist ➔Pirtobrutinib for the Treatment of Elderly Patients With Chronic Lymphocytic Leukemia
📍 Ohio State University Comprehensive Cancer Center — Columbus, Ohio
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
View Study & Checklist ➔A Study of Pirtobrutinib in Participants With Immune Thrombocytopenia
📍 USC Norris Comprehensive Cancer Center — Los Angeles, California
Immune Thrombocytopenia (ITP)
View Study & Checklist ➔LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies
📍 Froedtert & the Medical College of Wisconsin — Milwaukee, Wisconsin
Non Hodgkin Lymphoma
View Study & Checklist ➔A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
📍 Ironwood Cancer & Research Centers — Chandler, Arizona
Chronic Lymphocytic Leukemia
View Study & Checklist ➔A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
📍 University of Alabama At Birmingham Hospital — Birmingham, Alabama
Chronic Lymphocytic Leukemia
View Study & Checklist ➔